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Abstract The Nottingham prognostic index plus (NPI?) is
based on the assessment of biological class combined with
established clinicopathologic prognostic variables provid-
ing improved patient outcome stratification for breast
cancer superior to the traditional NPI. This study aimed to
determine prognostic capability of the NPI? in predicting
risk of development of distant disease. A well-charac-
terised series of 1073 primary early-stage BC cases treated
in Nottingham and 251 cases from Budapest were
immunohistochemically assessed for cytokeratin (Ck)5/6,
Ck18, EGFR, oestrogen receptor (ER), progesterone
receptor, HER2, HER3, HER4, Mucin 1 and p53 expres-
sion. NPI? biological class and prognostic scores were
assigned using individual algorithms for each biological
class incorporating clinicopathologic parameters and
investigated in terms of prediction of distant metastases-
free survival (MFS). The NPI? identified distinct prog-
nostic groups (PG) within each molecular class which were
predictive of MFS providing improved patient outcome
stratification superior to the traditional NPI. NPI? PGs,
between series, were comparable in predicting patient
outcome between series in luminal A, basal p53 altered and
HER2?/ER? (p[ 0.01) tumours. The low-risk groups
were similarly validated in luminal B, luminal N, basal p53
normal tumours (p[ 0.01). Due to small patient numbers
the remaining PGs could not be validated. NPI? was
additionally able to predict a higher risk of metastases at
certain distant sites. This study may indicate the NPI? as a
useful tool in predicting the risk of metastases. The NPI?
provides accurate risk stratification allowing improved
individualised clinical decision making for breast cancer.
Keywords Breast cancer  Classification  Prognostic
index  Molecular  Clinical  Outcome
Introduction
Breast cancer (BC) is remarkably heterogeneous with
respect to genotypic, phenotypic and behavioural charac-
teristics and subsequent response to treatment. With an
increasing number of treatment options available for BC
patients, deciding the most appropriate choice remains
challenging. However, accurate personalised BC treatment
requires robust and accurate risk stratification based on
both outcome prediction and biology of tumours [1],
combined with therapeutic modality response and resis-
tance assessment.
The Nottingham prognostic index (NPI) [2–5] is based
on histopathological factors (tumour size, lymph node
stage and tumour grade) and is used to stratify BC patients
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with operable early-stage primary BC into prognostic
groups. The NPI accuracy has been confirmed using long-
term patient follow-up [2], validated in large independent
multi-centre studies [3, 6], revised in order to stratify
patients into additional prognostic groups [7], and is cur-
rently adopted in clinical practice in the UK and other parts
of Europe and Australia. However, the NPI does not con-
sider the biological heterogeneity of BC and it therefore
needs further refinement to support a more sophisticated
personalised management of patients.
We have therefore developed a biomarker-based
prognostic index, Nottingham prognostic index plus
(NPI?) [8], using a large well-characterised series of
early-stage BC. NPI? is based on the well-established
clinicopathologic variables used in the NPI but has been
refined to integrate with tumour biology. It utilises routine
formalin-fixed clinical samples and immunohistochem-
istry (IHC) thus providing an easy adoption into the
current international clinical practice. NPI? is based on a
two-tier evaluation; initially the biological class of the
tumour is determined and is then combined with clini-
copathologic prognostic variables resulting in bespoke
NPI-like formulae for each biological class [8–11]. NPI?
is able to assist in predicting long-term patient survival
and to support clinical decision making in BC manage-
ment [8]. Breast tumours are classified into seven core BC
biological classes by the evaluation and combination of
10 BC-related biomarkers using IHC [12]. The molecular
classes identified are three luminal classes (Luminal A, N
and B), two basal classes (Basal—p53 altered and
Basal—p53 normal) and two HER2? classes (HER2?/
ER? and HER2?/ER-). Each biological class is further
stratified using a set of well-defined prognostic clinico-
pathologic variables which are combined in tailored for-
mulae to stratify each individual molecular class into
several prognostic subgroups (NPI? Groups) which are
superior to the classic NPI [8]. Recently, we have further
refined the NPI? algorithms and validated the NPI? in
an independent series of primary BC confirming its
reproducibility in providing accurate risk stratification
allowing improved individualised clinical decision mak-
ing for BC [13].
In this study, we aimed to determine the applicability of
NPI? to predict risk of distant metastases in two series of
clinically annotated early-stage primary invasive BC.
Patients and laboratory methods
Nottingham series
A series of 1073 patients from the Nottingham-Tenovus
Primary Breast Carcinoma Series, aged 70 years or less,
presenting with primary operable (stages I, II and IIIa)
invasive BC between 1986 and 1998 were previously used
to develop the NPI? [8–11]. This is a well-characterised
consecutive series of patients who were uniformly treated
according to locally agreed clinical protocols (Abd El-
Rehim et al. [9]). All tumours were less than 5 cm diameter
on clinical/pre-operative measurement and/or on operative
histology (T1 and T2). Women aged over 70 years were
not included because of the increased confounding effect of
comorbidities/death from other causes and because the
primary treatment protocols for elderly patients often dif-
fered from those for younger women. Adjuvant systemic
therapies were offered according to the Nottingham prog-
nostic index (NPI) and hormone receptor (HR) status [2, 7].
Patients in the Moderate I group (NPI 3.41–4.4) with HR-
positive tumours were offered hormonal therapy. Patients
in the Moderate II (NPI 4.41–5.4) and Poor (NPI[ 5.41)
groups received hormone therapy for HR-positive tumours
and cytotoxic therapy (classical cyclophosphamide,
methotrexate and 5-fluorouracil (CMF)) for HR-negative
tumours and if the patient was fit enough to tolerate
chemotherapy. Hormonal therapy was given to 396 patients
(40.3 %), chemotherapy to 213 (19.9 %). Only 19 patients
(1.9 %) received a combination of chemotherapy and
endocrine therapy (Table 1). Data relating to survival were
collated in a prospective manner for those patients pre-
senting after 1989 only. All samples from Nottingham used
in this study were pseudo-anonymised and collected prior
to 2006 and therefore under the Human Tissue Act
informed patient consent was not needed. Release of data
was also pseudo-anonymised as per Human Tissue Act
regulations.
Budapest series
This series comprised 368 screen detected and symp-
tomatic consecutive cases diagnosed with primary breast
cancer between 1999 and 2002 and operated at the Buda
MA´V hospital, Budapest, Hungary. A total of 251 cases
were assembled in TMAs; the remaining cases were not
included due to technical reasons or lack of relevant data.
The age range of patients was 30–88 years, and patholog-
ical size was 14 cm and less. All pT stages and inflam-
matory breast cancers were included. A total of 42.4 % of
the patients received the classical Bonadonna
scheme (CMF), at the time the standard chemotherapy,
unless comorbidities or advanced age permitted. Patients
with hormone receptor positive invasive tumours were
treated with Tamoxifen. According to the radiation therapy
recommendations valid at the time, loco-regional radiation
therapy was added to the postoperative treatment in cases
of breast conservation and in those patients undergoing
mastectomy who had 4 or more axillary lymph node
metastases (134 patients, 57.4 %). Pathological features
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were retrieved from the pathology reports and slides were
reviewed. Treatment data were collected from patients’
medical records. The evaluation was approved by the
Institutional Review Board of Semmelweis University
(IKEB, #185/2007). No informed consent was required by
the Institutional Ethical Committee.
Pathological characteristics of both series are sum-
marised in Table 1. Metastases-free survival (MFS) is
defined as the interval (in months) between the primary
surgery and occurrence of metastases being scored as an
event. Metastases did not include local (ipsilateral) or
regional recurrences, contralateral breast cancer. Lymph
node metastases did not include regional lymph nodes.
Patients who did not have metastatic disease were censored
at the time of last follow-up.
This study was approved by the Nottingham Research
Ethics Committee 2 under the title ’Development of a
molecular genetic classification of breast cancer’.
Determination of NPI1 biological class
Immunohistochemical reactivity for the NPI? biomarkers in
the Nottingham series was previously determined using
standard immunocytochemical techniques on tumour samples
prepared as tissue microarrays (TMAs) [9]. The NPI?
biomarkers used for classification were oestrogen receptor
(ER), progesterone receptor (PgR), cytokeratin (CK) 5/6,
CK7/8, epidermal growth factor receptor (EGFR; HER1),
c-erbB2 (HER2), c-erbB3 (HER3), c-erbB4 (HER4), p53, and
Mucin 1 [11]. TMAs of the Budapest series were additionally
stained for theNPI? biomarkers using the same procedures as
previously described [9, 11]. The Budapest TMAs consisted
of 2 mm tissue cores and were produced as previously
described [14]. Each tumour was represented by two cores.
Levels of immunohistochemical reactivity were determined
bymicroscopic assessment using the modified Histochemical
score (H score), giving a semi-quantitative assessment of both
the intensity of staining and the percentage of positive cells
(values between 0 and 300) [15, 16]. For HER2, the American
Society of Clinical Oncology/College of American Patholo-
gists Guidelines Recommendations for HER2 Testing in
Table 1 Pathological characteristics of the Nottingham and Budapest
series
Nottingham
n (%)
Budapest
n (%)
p value
Grade
1 158 (14.7) 102 (40.8)
2 348 (32.4) 72 (28.8) \0.001
3 567 (52.8) 76 (30.4)
Tubule formation
1 53 (5.0) 36 (15.1)
2 346 (33.0) 57 (23.8) \0.001
3 651 (62.0) 146 (61.1)
Pleomorphism
1 19 (1.8) 57 (23.4)
2 378 (36.1) 93 (38.1) \0.001
3 651 (62.1) 94 (38.5)
Mitosis
1 349 (33.2) 114 (47.5)
2 190 (18.1) 73 (30.4) \0.001
3 511 (47.6) 53 (22.1)
Size 0.13–10 cm
(median
2.0 cm)
0.3–14 cm
(median
2.1 cm)
\1.5 cm 240 (22.4) 68 (27.1) 0.111
C1.5 cm 833 (77.6) 183 (72.9)
Stage
1 654 (61.0) 88 (48.1)
2 330 (30.8) 55 (30.1) \0.001
3 88 (8.2) 40 (21.9)
Lymph nodes positive
0 608 (48.9) 90 (48.9)
1–3 318 (31.6) 55 (29.9) \0.001
4–9 70 (7.0) 29 (15.8)
[9 11 (1.1) 10 (5.4)
Nottingham prognostic index
Excellent 110 (10.3) 27 (14.8)
Good 200 (18.6) 31 (17.0)
Moderate 1 293 (27.3) 45 (24.7)
Moderate 2 277 (25.8) 39 (21.4) 0.008
Poor 140 (13.0) 20 (11.0)
Very poor 45 (4.2) 20 (11.0)
Chemotherapy
No 807 (75.2) 141 (57.6)
Yes 213 (19.9) 104 (42.4) \0.001
Metastases
Yes 363 (33.9) 49 (21.1) \0.001
No 707 (66.1) 183 (78.5)
Site of metastases
Bone 219 (20.5) –
Brain 57 (5.3) –
Liver 149 (13.9) –
Table 1 continued
Nottingham
n (%)
Budapest
n (%)
p value
Lung 91 (8.5) –
Lymph node 50 (4.7) –
Pleura 35 (3.3) –
Visceral 24 (2.3) –
Other 51 (4.8) –
Metastases-free
survival (months)
0–243
(median 119)
0–123
(median 96)
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Breast Cancer were used for assessment [17]. Equivocal (2?)
HER2? cases were confirmed by FISH/CISH [18]. The
Reporting Recommendations for Tumour Marker Prognostic
Studies (REMARK) criteria [19] were followed.
Determination of NPI1 score
For biological classification, a fuzzy logic rule-based
method algorithm was used where the cut-offs for each
biomarker were previously determined [12]. In particular,
the median value of markers was used for ER, PgR, CK7/8,
HER3, HER4 and MUC1. The expertise values were used
for those markers which had a median equal to zero and for
those where clinicians were sure about the value to con-
sider (CK5/6, EGFR, p53 and HER2).
The NPI? prognostic groups were calculated using
bespoke NPI-like formulae, previously developed for each
NPI? biological class of the Nottingham series, utilising
the existing available clinicopathological parameters [8].
Briefly, these were established by utilisation of the Beta
values generated by Cox regression analysis in predicting
breast cancer-specific survival of the well-established
histopathologic prognostic factors. These formulae were
initially derived from the Biological Classes in Green et al.
[11] and were subsequently refined using the improved
biological classification used in Soria et al. [12] consisting
of number of positive nodes, pathological tumour size,
Table 2 Distribution of NPI?
biological classes within the
Nottingham and Budapest
Series
NPI? class Nottingham (n = 1035) n (%) Budapest (n = 266) n (%) p value
Luminal A 288 (27.8) 84 (31.6) 0.005
Luminal N 205 (19.8) 32 (12.0)
Luminal B 186 (18.0) 65 (24.4)
Basal p53 altered 113 (10.9) 18 (6.8)
Basal p53 normal 96 (9.3) 36 (13.5)
HER2?/ER? 62 (6.0) 15 (5.6)
HER2?/ER- 85 (8.2) 16 (5.0)
Table 3 Clinicopathological parameters of the NPI? breast cancer biological classes in the Budapest series
Luminal A
(n = 84)
Luminal N
(n = 32)
Luminal B
(n = 64)
Basal—p53
altered (n = 18)
Basal—p53
normal (n = 23)
HER2?/
ER?
(n = 8)
HER2?/
ER-
(n = 3)
Cramer’s V
(p value)
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Size
\15 mm 24 (30.0) 10 (30.6) 19 (30.6) 7 (46.7) 1 (3.7) 2 (13.3) 3 (18.8) 0.235 (0.034)
C15 mm 56 (70.0) 21 (69.4) 43 (69.4) 8 (53.3) 26 (96.3) 13 (86.7) 13 (81.3)
Grade
1 44 (55.0) 22 (71.0) 26 (42.6) 1 (6.7) 5 (18.5) 3 (20.0) 0 0.378 (\0.001)
2 20 (25.0) 6 (19.4) 23 (37.7) 3 (20.0) 5 (18.5) 8 (53.3) 5 (31.3)
3 16 (20.0) 3 (9.7) 12 (19.7) 11 (73.3) 17 (63.0) 4 (26.7) 11 (68.8)
LN stage
1 34 (61.8) 8 (42.1) 21 (46.7) 4 (33.3) 12 (52.2) 4 (26.7) 4 (36.4) 0.211 (0.188)
2 12 (21.8) 7 (36.8) 17 (37.8) 2 (16.7) 5 (21.7) 6 (40.0) 4 (36.4)
3 9 (16.4) 4 (21.1) 7 (15.6) 6 (50.0) 6 (26.1) 5 (33.3) 3 (27.3)
NPI
Excellent 13 (23.6) 4 (21.1) 8 (17.8) 0 1 (4.3) 1 (6.7) 0 0.239 (0.010)
Good 13 (23.6) 6 (31.6) 8 (17.8) 0 3 (13.0) 1 (6.7) 0
Moderate
1
16 (29.1) 5 (26.3) 11 (24.4) 2 (18.2) 5 (21.7) 4 (26.7) 1 (9.1)
Moderate
2
6 (10.9) 1 (5.3) 7 (15.6) 6 (54.5) 5 (21.7) 6 (40.0) 6 (54.5)
Poor 4 (7.3) 1 (5.3) 7 (15.6) 2 (18.2) 4 (17.4) 0 2 (18.2)
Very poor 3 (5.5) 2 (10.5) 4 (8.9) 1 (9.1) 5 (21.7) 3 (20.0) 2 (18.2)
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stage, tubule formation, nuclear pleomorphism and
mitotic counts. These were identified as the most signifi-
cant variables in the Nottingham series impacting on
survival, according to their Beta value in Cox regression
indicating the magnitude of the influence of the hazard.
The Nottingham series was split into the NPI? biological
classes, and Cox regression analyses were performed
independently for each class to identify the most signifi-
cant clinicopathological prognostic factors and their beta
value in the context of the individual classes. NPI?
Prognostic Groups for the Budapest series were assigned
using the categorical cut-points previously derived from
the Nottingham series in each of the NPI? biological
classes [8]. For this purpose, the original pathology
assessments on full-face sections for the histopathologic
parameters were utilised.
Statistical analysis
The association between BC classes and both histopatho-
logical and clinical characteristics was assessed using
Cramer’s V [20] to produce p values. MFS differences
between NPI? biological classes and NPI? Groups were
determined using Kaplan–Meier curves using Log Rank. A
p\ 0.01 was considered significant with Bonferroni
adjustment for multiple testing.
Results
NPI1 in the Nottingham and Budapest series
There were significant differences in the distribution of
grade and stage (both p\ 0.001) of the breast tumours
between the Nottingham and Budapest series with a larger
proportion of the Nottingham series of a higher grade and
lower stage (Table 1). The median follow-up for the Not-
tingham series was 9.9 years and the Budapest series was
8.1 years. A total of 363 (33.9 %) and 49 (21.2 %) patients
developed distant metastases during the follow-up period
in the Nottingham and Budapest series, respectively. There
was, however, no difference in the MFS between the two
series (p = 0.236, Supplementary Fig. 1). The classic NPI
significantly predicted MFS in both the Nottingham (Sup-
plementary Fig. 1B, p\ 0.001) and Budapest (Supple-
mentary Fig. 1C, p\ 0.001) series.
There was either very good (ER, PgR, CK7/8, EGFR,
p53 and MUC1) or good (CK5/6 and HER4) concordance
between the expression for the majority of markers across
the two stained TMA cores whereas HER3 showed only
moderate concordance (Supplementary Table 1). NPI?
biological class was determined in the Budapest series
using the immunohistochemical data for the 10 NPI?
biomarkers. There was a difference in the distribution
between each of the seven NPI? biological classes (lu-
minal A, luminal N, luminal B, basal p53 altered, basal p53
normal, HER2?/ER? and HER2?/ER-) in Budapest
series compared with the Nottingham series (p\ 0.001,
Table 2). This was mainly due to the higher proportion of
luminal B tumours in the Budapest series. A total of 5 cases
(2.0 %) were not assigned to any class. There were sig-
nificant associations between the clinicopathological
parameters of the Budapest series and the NPI? biological
classes (Table 3). When comparing the MFS between the
Nottingham and Budapest series, there were no significant
differences in any of the luminal or basal NPI? biological
classes (Supplementary Fig. 2).
Bespoke NPI? formulae, based on nodal number,
tumour size, stage, and mitosis, for each of the seven
NPI? biological classes Rakha et al. [8] were applied to
produce an NPI? score, and then patients were further
stratified into NPI? Groups using the categorical cut-
points derived from the Nottingham series. The NPI?
score for the Budapest and Nottingham series was not
significantly different from each other (mean = 2.71 vs.
2.10, p = 0.179).
Table 4 Distribution of the NPI? Groups in the Budapest and
Nottingham series
NPI? Group Budapest
(n = 178)
Nottingham
(n = 828)
p value
n (%) n (%)
Luminal A
Low risk 23 (12.9) 148 (17.9) \0.001
Moderate risk 24 (13.5) 83 (10.0)
High risk 8 (4.5) 25 (3.0)
Luminal N
Low risk 18 (10.1) 133 (16.1)
High risk 1 (0.6) 17 (2.1)
Luminal B
Low risk 41 (23.0) 77 (9.3)
High risk 2 (1.1) 58 (7.0)
Basal—p53 altered
Low risk 7 (3.9) 86 (10.4)
High risk 4 (2.2) 10 (1.2)
Basal—p53 normal
Low risk 24 (13.5) 44 (5.4)
High risk 0 28 (3.4)
HER2?/ER?
Low risk 4 (2.2) 31 (3.7)
High risk 11 (6.2) 25 (3.0)
HER2?/ER-
Low risk 11 (6.2) 55 (6.6)
High risk 0 8 (1.0)
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Although there was a significant difference in the dis-
tribution of the NPI? Groups between the Nottingham and
Budapest series (Table 4, p\ 0.001), a similar number of
NPI? Groups were evident in each of the Biological
classes in both series Rakha et al. [8]. However, some of
the poor prognostic groups were under-represented in the
Budapest series due to the relatively lower frequency of
highly proliferative tumours in the series.
NPI1 and risk of distant metastases
In the Nottingham Series, the biological classes were sig-
nificantly associated with patient MFS where the luminal A
(HR 1.57, p = 0.006) and luminal N (HR 1.49, p = 0.024)
classes had a significantly better survival than the luminal
B class (Figs. 1, 2). Luminal A tumours also had a sig-
nificantly better MFS than basal p53 altered (HR 1.49,
p = 0.043), basal p53 normal (HR 1.80, p = 0.003),
HER2?/ER? (HR 2.69, p\ 0.001) and HER2?/ER-
(HR 2.47, p\ 0.001) tumours. Similarly, luminal N
tumours had a significantly longer MFS than basal p53
normal (HR 1.66, p = 0.014), HER2?/ER? (HR 2.47,
p\ 0.001) and HER2?/ER- (HR 2.19, p\ 0.001)
tumours but not the basal-p53 altered class (p = 0.135).
There was no significant difference in MFS between basal
p53 altered and basal p53 normal with the HER2?/ER? or
HER2?/ER- classes.
The NPI? was used to determine the effect on MFS in
the different molecular classes where NPI? outcome pre-
diction was compared with that achieved by the traditional
NPI in each of the biological classes (Fig. 2a–n). In addi-
tion to improved outcome prediction using NPI? com-
pared with the traditional NPI in each class, NPI? provided
more clinically relevant stratification with splitting of each
class into two or three prognostic groups compared with
the six classes of NPI.
When comparing the patient outcome in each of the
NPI? prognostic groups between the Nottingham and
Budapest Series, there were no significant differences in
MFS in the majority of them (Supplementary Fig. 2).
Certain high-risk NPI? Groups (luminal N; luminal B;
basal p53 normal and HER2?/ER) could not be validated
due to being under-represented in the Budapest series.
NPI? Groups were additionally able to predict a higher
risk of metastases to certain distant sites, summarised in
Table 5. Bone metastases were significantly more likely to
occur in the poor prognostic group of the luminal B, basal
p53 altered, HER2?/ER? and HER2?/ER- classes and a
lower risk in the good prognostic group of luminal A, basal
p53 normal, HER2?/ER? and HER2?/ER- classes. Lung
metastases were associated with the higher risk groups of
Basal, HER2? and luminal N tumours. Metastases to the
brain were associated with HER2? tumours only,
Luminal A n=71
Luminal N n=28
Luminal B n=59
Basal p53 altered n=14
Basal p53 normal n=25
HER2+/ER+ n=15
HER2+/ER- n=15
HR=0.71 (0.19-2.55) p=0.591
HR=0.93 (0.37-2.35) p=0.870
HR=3.40 (1.24-9.36) p=0.018
HR=2.42 (0.92-6.37) p=0.073
HR=3.21 (1.10-9.42) p=0.033
HR=4.53 (1.71-11.95) p=0.002 
}
}
}
}
}
}
A
Luminal A n=288
Luminal N n=205
Luminal B n=186
Basal p53 altered n=113
Basal p53 normal n=96
HER2+/ER+ n=62
HER2+/ER- n=85
HR=1.14 (0.82-1.59) p=0.446
HR=1.52 (1.09-2.13) p=0.014
HR=1.45 (0.98-2.16) p=0.064
HR=1.75 (1.17-2.61) p=0.006
HR=2.56 (1.69-3.88) p<0.001
HR=2.32 (1.58-3.41) p<0.001
}
}
}
}
}
}
p=0.001Bp=0.001
Fig. 1 MFS with respect to NPI? biological classes. a Nottingham and b Budapest series
cFig. 2 Patient stratification for MFS with the classic NPI (left)
compared with NPI? (right) in each of the biological classes in the
Nottingham series. a–b luminal A, c–d luminal N, e–f luminal B, g–
h basal p53 altered, i–j Basal p53 normal, k–L HER2?/ER?, m–
n HER2?/ER-. EPG excellent prognostic group, GPG good
prognostic group, MPG moderate prognostic group, PPG poor
prognostic group, VPG very poor prognostic group
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Low risk n=148
Moderate risk n=83
High risk n=25
EPG n=42
GPG n=61
MPG1 n=74
MPG2 n=50
PPG n=24
VPG n=5A B p<0.001p<0.001
Low risk n=133
High risk n=17
EPG n=30
GPG n=54
MPG1 n=34
MPG2 n=22
PPG n=7
VPG n=3C D p<0.001p<0.001
Low risk n=77
High risk n=58
EPG n=15
GPG n=30
MPG1 n=33
MPG2 n=35
PPG n=19
VPG n=3E F p<0.001p=0.011
Low risk n=86
High risk n=10
MPG1 n=39
MPG2 n=36
PPG n=15
VPG n=6G H p<0.001p=0.067
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irrespective of ER status, with poor prognostic tumours
having a higher incidence of brain metastases compared
with good prognostic tumours. A higher incidence of liver
metastases were associated with moderate and poor prog-
nostic luminal A tumours and luminal B poor prognostic
tumours compared with luminal A good prognostic
tumours which had a significantly lower incidence
(p\ 0.001). Additionally, basal, both p53 altered and
normal tumours, in NPI? high-risk groups had a signifi-
cantly higher incidence of liver metastases than basal p53
normal tumours in the low risk group. There was no
association between NPI? and number of metastatic sites
(data not shown).
Discussion
Contemporary treatment of BC requires the integration of
clinicopathological and biological information to ensure
effective stratification of patients with regard to their
Low risk n=44
High risk n=28
EPG n=1
GPG n=5
MPG1 n=20
MPG2 n=28
PPG n=18
I J p=0.001p=0.286
K L P<0.001p<0.001
Low risk n=31
High risk n=25EPG n=1GPG n=2
MPG1 n=19
MPG2 n=14
PPG n=14
VPG n=6
Low risk n=55
High risk n=8
EPG n=1
GPG n=5
MPG1 n=16
MPG2 n=23
PPG n=10
VPG n=8
M N P<0.001p<0.001
Fig. 2 continued
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expected outcome and response to the ever increasing
treatment options. Molecular gene assays, such as Onco-
type DX [21] and MammaPrint [22], are limited in their
clinical utility for the management of BC due to factors
including reproducibility, validation, cost and targeting
only certain BC patients.
We have developed the NPI? based on the integration
of clinical, histopathological and biological data; we
determined using routine clinical methodology, which is
envisaged to assist clinicians in offering a more person-
alised adjuvant treatment plan in all early-stage BC
patients. Whilst the clinical utility of NPI? in predicting
patient survival has previously been determined [8], we had
previously not explored the capability of NPI? with
respect to prediction of risk of metastases. We therefore
sought to confirm the prognostic capabilities of NPI? in
predicting risk of metastases in two independent European
series of BC (Nottingham and Budapest).
NPI? uses well-established powerful clinicopathologic
variables to stratify each of the biological classes into
clinically distinct subgroups using bespoke NPI-like for-
mulae. In the Nottingham series, each biological class was
previously stratified into at least two prognostic groups
which were predictive of breast cancer-specific survival
[8]. Using these prognostic groups, we further show that
the NPI? can predict either a low or high risk of devel-
oping metastases after receiving standard adjuvant therapy.
The combination of biological class and clinicopathologi-
cal parameters used in the NPI? provided enhanced
prognostic information for patients with BC into more
clinically relevant subgroups compared with the classic
NPI. Those patients with an adverse risk of tumour relapse
are clearly identified as candidates for additional or alter-
native forms of therapy as the conventional BC manage-
ment at the time of diagnosis has failed to minimise
metastatic disease. We also confirm that biological sub-
types of BC are associated with particular metastatic
behaviour where bone metastases were common across all
biological subtypes, whereas brain metastases were
specifically associated with HER2? tumours [23].
We further sought to validate and confirm the prognostic
capabilities of NPI? in an independent series of BC from a
separate centre (Budapest, Hungary). Although there was
some difference in the overall distribution of size, stage
and grade of tumours between the Nottingham and Hun-
gary series, the number of NPI? biological classes was
Table 5 NPI? prognostic
groups and site of distant
metastases
Site of distant metastases
Bone Liver Lung Brain
n (%) p value n (%) p value n (%) p value n (%) p value
Luminal A
Low risk 15 (10.1) \0.001 9 (6.1) \0.001 3 (2.0) 0.002 4 (2.7) \0.001
Moderate risk 20 (24.1) 17 (20.5) 13 (15.7) 4 (4.8)
High risk 10 (40.0) 8 (32.0) 3 (12.0) 4 (16.0)
Luminal N
Low risk 21 (15.8) 12 (9.0) 13 (9.8) 3 (2.3)
High risk 8 (47.1) 3 (17.6) 3 (17.6) 1 (5.9)
Luminal B
Low risk 11 (14.3) 7 (9.1) 2 (2.6) 2 (2.6)
High risk 25 (43.1) 13 (22.4) 6 (10.3) 2 (3.4)
Basal p53 altered
Low risk 11 (12.8) 7 (8.1) 8 (9.3) 9 (10.5)
High risk 5 (50.0) 3 (30.0) 2 (20.0) 1 (10.0)
Basal p53 normal
Low risk 2 (4.5) 0 3 (6.8) 1 (2.3)
High risk 24 (14.3) 6 (21.4) 3 (10.7) 3 (10.7)
HER2?/ER?
Low risk 4 (12.9) 7 (22.6) 2 (6.5) 0
High risk 12 (48.0) 11 (44.0) 5 (20.0) 5 (20.0)
HER2?/ER-
Low risk 9 (16.4) 11 (20.0) 4 (7.3) 2 (3.6)
High risk 3 (37.5) 3 (37.5) 3 (37.5) 3 (37.5)
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similar. This is consistent with the proportion of cancer
subtypes reported in our previous validation [13] and other
studies [9, 11, 22, 24–31], and further provides evidence
that the classification of BC into seven biological classes
can be achieved using a discrete panel of 10 proteins
assessed by immunohistochemistry.
In the Budapest series, the NPI? Prognostic Groups
showed comparable MFS when compared with the Not-
tingham series in NPI? biological classes: luminal A and
basal p53 altered. The NPI? Prognostic Groups with a low
risk of metastases were similarly validated in the NPI?
biological classes: luminal N, luminal B, basal p53 normal
along with the high risk NPI? Prognostic Group in the
HER2?/ER? class. However, due to very small numbers
of patients assigned in the Budapest series in the remaining
NPI? Prognostic Groups of biological classes, Luminal N,
Luminal B, Basal p53 normal and HER2?/ER- could not
be validated.
In conclusion, the NPI? can stratify patients with BC of
any biological class type into a category of expected low or
high risk of developing metastases following conventional
therapy and confirmed in an independent series of primary
BC. It is envisaged that an NPI? risk stratification index
score could be developed to replace assignment of patients
into either a good or adverse outcome group.
We confirm that the NPI? is a reproducible tool that
provides improved individualised clinical decision making
for breast cancer by refinement of clinical prediction.
Advantages in applying the NPI? in clinical decision
making for BC patients are improved prognostication and
risk stratification, and the potential for health economic
savings through appropriate targeted treatment. Addition-
ally, NPI? uses routine clinical samples and robust labo-
ratory methods integrating easily into current international
clinical practice. Further validation of the clinical validity
of NPI? using modern eta treatments in randomised clin-
ical trial material is therefore warranted.
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